How to Respond to HKEX Listing Committee Hearing Questions

The HKEX Listing Committee hearing has evolved from a procedural formality into the single most consequential gatekeeping event in a Hong Kong IPO, particularly for China-concept issuers deploying VIE structures. As of Q1 2025, the Listing Committee is rejecting or deferring approximately 18% of applications at the hearing stage — up from an estimated 8% in 2022 — driven by intensified scrutiny under HKEX Listing Rules Chapter 8 (Qualification for Listing) and the SFC’s March 2024 updated guidance on VIE arrangements (SFC Code of Conduct, para 17.6). For a sponsor-led Main Board application, the hearing represents the culmination of a 6–9 month process involving at least three rounds of exchange comments, and the margin for error is measured in hours of preparation, not days. This article dissects the mechanics of a successful hearing response, drawing on 2024–2025 precedents including the deferred applications of two PRC-consumer-tech issuers and the approved listing of a Cayman-incorporated, PRC-headquartered biotech firm in November 2024. It provides a structured framework for sponsors, company secretaries, and legal counsel to anticipate, prepare, and deliver responses that satisfy the Committee’s three core concerns: business viability, structural compliance, and investor protection.

The Pre-Hearing Document Package: Structuring the Written Response

The Listing Committee does not evaluate oral answers in isolation. Its decision is heavily influenced by the written response submitted 48 hours before the hearing, pursuant to HKEX Guidance Letter HKEX-GL86-16 (updated January 2024). This document, typically 80–120 pages for a Main Board applicant, must pre-emptively address every material issue raised in the exchange’s final comment letter.

Prioritising the VIE Structural Risk Disclosure

For PRC-incorporated or Cayman-incorporated issuers with VIE structures, the written response must include a dedicated section on structural risk mitigation. The SFC’s March 2024 circular on VIE arrangements explicitly requires that the prospectus (招股書) disclose the contractual mechanisms by which the offshore listed entity controls the PRC operating company, including the specific provisions of the VIE agreements (e.g., exclusive option agreements, equity pledge agreements, and power of attorney). The written response should cross-reference each agreement to the relevant HKEX Listing Rule, particularly Rule 8.04 (control over the business) and Rule 8.05 (profit track record). A 2024 case study: the deferred application of a PRC-edtech issuer cited insufficient detail on the enforceability of VIE agreements under PRC Contract Law (Article 52) as a primary reason for the Committee’s request for further submissions.

Financial Projections and the Profit Forecast Requirement

The Committee frequently requests a profit forecast for the current financial year, even when the applicant does not include one in the prospectus. Under HKEX Listing Rule 11.16, a profit forecast in a listing document must be reported on by the sponsor and the reporting accountant. The written response should include a sensitivity analysis showing the impact of a 10% revenue decline on net profit, cash flow from operations, and working capital. In the November 2024 biotech approval, the applicant provided a 24-month cash flow projection demonstrating runway of 18 months at the forecast burn rate, which satisfied the Committee’s concern under Rule 8.07 (sufficient working capital for at least 12 months from listing date). The response should also include a reconciliation of the forecast to historical financial data from the track record period, audited under Hong Kong Financial Reporting Standards (HKFRS) or International Financial Reporting Standards (IFRS).

Legal Due Diligence and the Sponsor’s Comfort Letter

The written response must attach a sponsor’s comfort letter covering the legal due diligence findings, particularly on PRC regulatory approvals. As of 2025, the Committee is requiring explicit confirmation that the issuer has obtained all necessary approvals from the China Securities Regulatory Commission (CSRC) under the revised Filing Rules for Overseas Securities Offerings and Listings (effective March 31, 2023). The response should include a table listing each PRC regulatory approval, the issuing authority, and the date of issuance. For issuers in regulated industries — such as fintech, healthcare, or education — the response must also address any pending or threatened regulatory changes. The December 2024 case of a PRC-fintech issuer’s hearing deferral was directly linked to incomplete documentation on the PBOC’s stance on third-party payment licences.

The Oral Hearing: Structure, Timing, and Key Personnel

The Listing Committee hearing itself typically lasts 90 to 120 minutes, with 45–60 minutes allocated to the applicant’s presentation and the remainder to questions. The Committee comprises 25 members, but a quorum of 8–10 is present for any given hearing, including at least two members from the SFC and two from the HKEX Listing Division.

The Presentation: The First 15 Minutes

The applicant’s presentation should be delivered by the CEO or CFO, supported by the sponsor’s lead banker and the legal counsel. The first 15 minutes must cover three points in sequence: (1) a one-minute summary of the business model, (2) a five-minute discussion of the VIE structure and its compliance with HKEX Guidance Letter HKEX-GL94-18, and (3) a nine-minute walkthrough of the financial highlights, focusing on revenue growth, gross margin, and cash flow. The Committee has zero tolerance for marketing language; every claim must be backed by a page reference to the prospectus (招股書) or the written response. A 2024 survey of Listing Committee members, conducted by the Hong Kong Institute of Directors, found that 78% of members consider the first 15 minutes dispositive for their initial impression.

Handling Questions on Business Sustainability

The most common line of questioning concerns business sustainability, particularly for issuers with a narrow product line or high customer concentration. The Committee will test the applicant’s assumptions using the sponsor’s own due diligence report. For example, if the top three customers represent more than 50% of revenue, the Committee will ask for the specific contractual terms of those customer agreements, including renewal clauses, pricing mechanisms, and termination rights. The response must reference the written response section on customer concentration, which should include a sensitivity analysis showing the impact of losing the top customer on revenue, gross profit, and net income. Under HKEX Listing Rule 8.05(1)(a), the issuer must demonstrate a trading record of at least three financial years, and the Committee will probe whether the revenue trajectory is sustainable without the top customer.

Questions on Connected Transactions and Corporate Governance

For issuers with significant connected transactions — defined under HKEX Listing Rules Chapter 14A as transactions exceeding 0.1% of the issuer’s market capitalisation — the Committee will require a detailed explanation of the pricing methodology, the approval process, and the ongoing monitoring mechanism. The response should include a table listing each connected transaction, the relationship to the connected person, the transaction value, and the percentage of the issuer’s revenue or assets affected. The Committee will also examine the composition of the board, particularly the independence of the independent non-executive directors (INEDs). Under Rule 3.10, the board must have at least three INEDs, and at least one must have appropriate professional qualifications or accounting or related financial management expertise. The November 2024 biotech issuer’s hearing was approved in part because its INEDs included a former SFC enforcement director and a Big Four audit partner, providing the Committee with confidence in the governance framework.

Post-Hearing Follow-Up: The Conditional Approval and Remedial Actions

Approximately 25% of hearing approvals in 2024 were conditional, meaning the Committee granted approval subject to the issuer addressing specific outstanding items within a defined timeline — typically 14 to 30 days. The sponsor must submit a written confirmation that all conditions have been satisfied before the listing can proceed.

Responding to Conditions on Legal and Regulatory Matters

A common condition involves the submission of additional legal opinions on PRC regulatory matters. For example, if the Committee was not fully satisfied with the enforceability of the VIE agreements under PRC law, the condition may require a supplementary opinion from a PRC law firm with specific expertise in foreign investment restrictions. The response must include a legal opinion that addresses each of the Committee’s concerns, citing specific PRC laws and regulations, such as the Foreign Investment Law (effective January 1, 2020) and the Catalogue of Industries for Guiding Foreign Investment (2022 edition). The opinion should also confirm that the VIE structure does not violate the negative list provisions.

Responding to Conditions on Financial Disclosures

Financial conditions typically require the inclusion of additional disclosure in the prospectus (招股書) or the filing of an updated profit forecast. If the Committee requested a sensitivity analysis on a specific risk factor — such as foreign exchange exposure or interest rate risk — the sponsor must provide a detailed quantitative analysis in the response. Under HKEX Listing Rule 11.17, any material change in the financial information after the hearing must be disclosed in a supplementary prospectus, which requires a further hearing if the change is deemed material by the Listing Division. The 2024 case of a PRC-consumer-tech issuer involved a condition requiring the issuer to disclose the impact of PRC tax incentives expiring in 2026, which required a 15-page supplementary analysis in the final prospectus.

Timing and the Listing Calendar

Once the conditions are satisfied, the issuer can proceed to the listing stage, which typically takes 5 to 10 business days for a Main Board IPO. The sponsor must file a formal confirmation with the HKEX Listing Division, including a certificate of compliance signed by the issuer’s directors and the sponsor. The listing date is then set by the HKEX, subject to market conditions and the availability of the trading floor. For 2025, the average time from hearing to listing was 12 business days for unconditional approvals and 22 business days for conditional approvals, based on HKEX data published in its January 2025 Quarterly Bulletin.

Key Takeaways for Sponsors and Issuers

• Submit the written response 48 hours before the hearing with a dedicated VIE structural risk section cross-referenced to HKEX Listing Rules Chapter 8 and the SFC’s March 2024 circular, including a table of all PRC regulatory approvals with issuing authority and date.
• Prepare the CEO/CFO presentation to cover business model, VIE compliance, and financial highlights in the first 15 minutes, with every statement backed by a prospectus page reference and no marketing language.
• Pre-empt customer concentration questions with a written sensitivity analysis showing the impact of losing the top customer on revenue, gross profit, and net income, supported by contractual terms from customer agreements.
• Ensure the board includes at least three INEDs with relevant expertise — such as former regulatory officials or Big Four partners — to satisfy the Committee’s governance concerns under Rule 3.10.
• Budget 14–30 days for post-hearing remedial actions on conditional approvals, with a formal sponsor confirmation and, if required, a supplementary legal opinion from a PRC law firm addressing specific VIE enforceability concerns under the Foreign Investment Law.